RESUMO
INTRODUCTION: Serotonergic agents have greater effectiveness than noradrenergic ones in the treatment of Panic Disorder (PD). However preliminary studies suggested that reboxetine might be effective in the treatment of PD. We compared the effectiveness and tolerability of reboxetine and paroxetine in the treatment of PD. METHODS: Sixty-eight patients with PD were assigned to treatment groups in a single-blind, randomized design. Each patient was assessed at day 0 and 90 by the Panic Associated Symptoms Scale (PASS), the Sheehan Disability Scale (SDS) and the Fear Questionnaire (FQ). Side effects were also recorded. RESULTS: Reduction of PASS scores was significantly greater in the paroxetine group than in the reboxetine one. Vice versa we did not find any significant differences for other outcome measures. Sexual dysfunction and weight gain were significantly less frequent in the reboxetine group. CONCLUSIONS: The results showed a greater effect of paroxetine on panic attacks than reboxetine, while no differences for anticipatory anxiety and avoidance were found, suggesting a different role of noradrenaline and serotonin in the treatment of PD.
Assuntos
Inibidores da Captação Adrenérgica/uso terapêutico , Morfolinas/uso terapêutico , Transtorno de Pânico/tratamento farmacológico , Paroxetina/uso terapêutico , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Adulto , Feminino , Humanos , Masculino , Psicometria , Reboxetina , Método Simples-CegoRESUMO
The behavior of HGH in basal conditions and after L-Dopa infusion was studied in a group of patients with diabetic retinopathy, in 9 obese and 8 control subjects. In both diabetics and obese subjects, increases found in HGH plasma levels after administration of the drug were slighter than in the controls. On the basis of these results it can be concluded that in diabetics the availability of energetic substrates may modify the HGH response to the L-Dopa stimulus. In obesity, the possibility is considered of a reversible response to the L-Dopa stimulus. In obesity, the possibility is considered of a reversible defect in the sensitivity of the dopaminergic receptors, induced by metabolic and endocrine factors.
